News & Events
Newsletter
Picture Gallery
 
Search On Site
 
   
 
 
 
Home | Media Room >News & Events Details

News & Events Details

Monday, February 02, 2015
Feboric Launch 2015
After successfully incorporating Tramapar (Paracetamol+Tramadol HCl) as an effective & successful orthopaedic pain management brand for the last 5 years, Efroze has again raise its product portfolio bars higher by launching a new product in orthopedic pain relief/management sector called “FEBORIC” (Febuxostat) tablets 40mg & 80mg.

FEBORIC contains Febuxostat, which belongs to the xanthine oxidase inhibitor group that has demonstrated effective pain relief in both acute and chronic gout pain management.

Feboric works by decreasing the amount of uric acid produced in the body. It is also used to prevent gout attacks.

Feboric is recommended in treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).
Back to News List
 
 
 
 
 
 
       
 
Copyright © Efroze Chemical Industries (pvt) Limited. All rights are reserved. Designed by EfroTech